AGE insider filings
AgeX Therapeutics, Inc. — 35 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-05-18. Screen AGE transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for AGE between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — AgeX Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-05-18 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 756,429 (derivative) @ $0 | EDGAR |
| 2023-03-22 | 4 | Juvenescence Ltd — Director, 10% owner | Gift (G): 16,447,500 @ $0 | EDGAR |
| 2023-03-14 | 4 | WEST MICHAEL D — Chief Executive Officer | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,060 @ $0.59 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 801,924 (derivative) @ $0 | EDGAR |
| 2023-02-08 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 340,136 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 847,457 (derivative) @ $0 | EDGAR |
| 2022-12-13 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.59 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2022-10-27 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 362,318 (derivative) @ $0 | EDGAR |
| 2022-09-13 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.56 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2022-08-24 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 746,380 (derivative) @ $0 | EDGAR |
| 2022-08-24 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 703,234 (derivative) @ $0 | EDGAR |
| 2022-06-14 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.77 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2022-04-14 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 568,440 (derivative) @ $0 | EDGAR |
| 2022-03-15 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,281 @ $0.69 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2022-03-11 | 4 | Juvenescence Ltd — Director, 10% owner | Grant/award (A): 5,230,768 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | Juvenescence Ltd — 10% owner | Purchase (P): 308,565 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Hackett Joanne M. — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2021-12-14 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.64 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2021-09-21 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $1.00 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2021-06-23 | 4 | Jenkins Annalisa — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2021-06-23 | 4 | MAY MICHAEL H — Director | Grant/award (A): 65,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2021-06-23 | 4 | Bailey Gregory — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2021-06-15 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $1.53 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | STERNBERG HAL — Vice President-Research | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | Park Andrea Eun Jae — Chief Financial Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | MALIK NAFEES NASEER — Chief Operating Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | SEGALL JUDITH — Director of Admin & Secretary | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2021-03-15 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,284 @ $2.03 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2021-02-09 | 4 | Juvenescence Ltd — 10% owner | Purchase (P): 263,852 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Juvenescence Ltd — 10% owner | Purchase (P): 328,947 (derivative) @ $0 | EDGAR |
| 2020-12-15 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $1.69 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2020-11-19 | 4 | Juvenescence Ltd — 10% owner | Purchase (P): 280,898 (derivative) @ $0 | EDGAR |
| 2020-10-06 | 4 | Juvenescence Ltd — 10% owner | Purchase (P): 588,235 (derivative) @ $0 | EDGAR |
| 2020-09-15 | 4 | WEST MICHAEL D — Chief Executive Officer, Director | Option exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.81 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
Recent 8-K events — AgeX Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-09 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-24 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | EDGAR |
Registration filings — AgeX Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-298536 (S-1) — latest: Initial registration (S-1), filed 2026-08-24
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AGE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs